These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26850527)

  • 1. The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye.
    Lanza NL; Valenzuela F; Perez VL; Galor A
    Ocul Surf; 2016 Apr; 14(2):189-95. PubMed ID: 26850527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients.
    Lanza NL; McClellan AL; Batawi H; Felix ER; Sarantopoulos KD; Levitt RC; Galor A
    Ocul Surf; 2016 Apr; 14(2):216-23. PubMed ID: 26807724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay.
    Messmer EM; von Lindenfels V; Garbe A; Kampik A
    Ophthalmology; 2016 Nov; 123(11):2300-2308. PubMed ID: 27665213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye.
    Sambursky R; Davitt WF; Latkany R; Tauber S; Starr C; Friedberg M; Dirks MS; McDonald M
    JAMA Ophthalmol; 2013 Jan; 131(1):24-8. PubMed ID: 23307206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of point-of-care test for elevated tear matrix metalloproteinase 9 in post-LASIK dry eyes.
    Chan TC; Ye C; Chan KP; Chu KO; Jhanji V
    Br J Ophthalmol; 2016 Sep; 100(9):1188-91. PubMed ID: 26682569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, multicenter, clinical evaluation of point-of-care matrix metalloproteinase-9 test for confirming dry eye disease.
    Sambursky R; Davitt WF; Friedberg M; Tauber S
    Cornea; 2014 Aug; 33(8):812-8. PubMed ID: 24977985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the Matrix Metalloproteinase 9 Point-of-Care Test Positivity According to MMP-9 Concentration and Loading Volume.
    Huh J; Choi SY; Eom Y; Kim HM; Song JS
    Cornea; 2020 Feb; 39(2):234-236. PubMed ID: 31369458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The practical detection of mmp-9 diagnoses ocular surface disease and may help prevent its complications.
    Kaufman HE
    Cornea; 2013 Feb; 32(2):211-6. PubMed ID: 22673852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of matrix metallopeptidase-9 expression following cyclosporine and diquafosol treatment in dry eye.
    So HR; Baek J; Lee JY; Kim HS; Kim MS; Kim EC
    Ann Med; 2023 Dec; 55(1):2228192. PubMed ID: 37354028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non-Dry Eye Patients.
    Schargus M; Ivanova S; Kakkassery V; Dick HB; Joachim S
    Cornea; 2015 Jul; 34(7):739-44. PubMed ID: 25909238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of matrix metalloproteinase-9 for the treatment of dry eye syndrome; a review study.
    Shoari A; Kanavi MR; Rasaee MJ
    Exp Eye Res; 2021 Apr; 205():108523. PubMed ID: 33662353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A highly soluble matrix metalloproteinase-9 inhibitor for potential treatment of dry eye syndrome.
    Mori M; De Lorenzo E; Torre E; Fragai M; Nativi C; Luchinat C; Arcangeli A
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):289-95. PubMed ID: 22520332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye.
    Sambursky R
    Clin Ophthalmol; 2016; 10():2337-2343. PubMed ID: 27920494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye.
    Pflugfelder SC; Farley W; Luo L; Chen LZ; de Paiva CS; Olmos LC; Li DQ; Fini ME
    Am J Pathol; 2005 Jan; 166(1):61-71. PubMed ID: 15632000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rethinking dry eye disease: a perspective on clinical implications.
    Bron AJ; Tomlinson A; Foulks GN; Pepose JS; Baudouin C; Geerling G; Nichols KK; Lemp MA
    Ocul Surf; 2014 Apr; 12(2 Suppl):S1-31. PubMed ID: 24725379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tear film osmolarity measurements in dry eye disease using electrical impedance technology.
    Jacobi C; Jacobi A; Kruse FE; Cursiefen C
    Cornea; 2011 Dec; 30(12):1289-92. PubMed ID: 22001814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ocular involvement and its' manifestations in rheumatoid arthritis patients].
    Markovitz E; Perry ZH; Tsumi E; Abu-Shakra M
    Harefuah; 2011 Sep; 150(9):713-8, 751. PubMed ID: 22026055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Error in Missing Journal Club Designation in: Sensitivity and Specificity of a Point-of-Care Matrix Metalloproteinase 9 Immunoassay for Diagnosing Inflammation Related to Dry Eye.
    JAMA Ophthalmol; 2013 Mar; 131(3):364. PubMed ID: 23753781
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential diagnosis of dry eye conditions.
    Pflugfelder SC
    Adv Dent Res; 1996 Apr; 10(1):9-12. PubMed ID: 8934916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current patterns in the use of diagnostic tests in dry eye evaluation.
    Smith J; Nichols KK; Baldwin EK
    Cornea; 2008 Jul; 27(6):656-62. PubMed ID: 18580256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.